Tadalafil effective, safe in complete erectile dysfunction

October 14, 2012
Tadalafil effective, safe in complete erectile dysfunction
In men with complete erectile dysfunction, tadalafil 2.5 and 5 mg once-daily result an in intercourse success rate of 32.4 and 46.4 percent, respectively, according to research published online Oct. 4 in The Journal of Sexual Medicine.

(HealthDay)—In men with complete erectile dysfunction (ED), tadalafil 2.5 and 5 mg once-daily result an in intercourse success rate of 32.4 and 46.4 percent, respectively, according to research published online Oct. 4 in The Journal of Sexual Medicine.

Ridwan Shabsigh, M.D., of the Maimonides Medical Center in New York City, and colleagues conducted a post-hoc, pooled analysis of results from four randomized, double-blind trials evaluating the effects of tadalafil 2.5 or 5 mg compared with placebo in men with complete ED (no successful intercourse attempts at baseline).

After 12 weeks of once-daily treatment with tadalafil, the researchers found that the mean per-patient Profile question 3 (SEP3) increased from 0 percent to 32.4 and 46.4 percent with 2.5 and 5 mg tadalafil, respectively. The SEP2 (successful penetration) increased from 21.1 to 48.2 percent and 24.4 to 66.2 percent with 2.5 and 5 mg tadalafil, respectively. The mean International Index of Erectile Function increased significantly with 2.5 and 5 mg tadalafil versus placebo. Compared with placebo, improvements were also noted in intercourse-satisfaction and overall-satisfaction domains. Tadalafil was well tolerated with no increase in versus placebo.

"Once-daily tadalafil 2.5 or 5 mg significantly enhanced erectile function (versus placebo) across all coprimary and secondary efficacy end points in this analysis, and was generally well tolerated," the authors write.

The four base studies and the reported analysis were sponsored by ; several authors disclosed to pharmaceutical companies, including Eli Lilly, which manufactures tadalafil.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

ECO: New weight loss drug effective in advanced obesity

May 14, 2012

(HealthDay) -- A new combination treatment of controlled-release phentermine/topiramate (PHEN/TPM CR) leads to significantly greater weight loss than a placebo even in individuals with significant obesity-related comorbidities, ...

Donepezil found helpful in dementia with lewy bodies

July 31, 2012

(HealthDay) -- For patients with dementia with Lewy bodies (DLB), treatment with 5 or 10 mg/day donepezil is associated with significant cognitive, behavioral, and global function improvements, according to research published ...

Recommended for you

Experimental MERS vaccine shows promise in animal studies

July 28, 2015

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. ...

Can social isolation fuel epidemics?

July 21, 2015

Conventional wisdom has it that the more people stay within their own social groups and avoid others, the less likely it is small disease outbreaks turn into full-blown epidemics. But the conventional wisdom is wrong, according ...

Lack of knowledge on animal disease leaves humans at risk

July 20, 2015

Researchers from the University of Sydney have painted the most detailed picture to date of major infectious diseases shared between wildlife and livestock, and found a huge gap in knowledge about diseases which could spread ...

IBD genetically similar in Europeans and non-Europeans

July 20, 2015

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.